A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

• Progression Free Survival [ Time Frame: Assessed every 12 weeks until progression. ] [ Designated as safety issue: No ]
  To evaluate the effect of the addition of idelalisib (GS-1101) to bendamustine/rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)
  
  

• Tumor control [ Time Frame: Assessed every 12 weeks until progression ] [ Designated as safety issue: No ]
  To evaluate the effect of the addition of idelalisib (GS-1101) to bendamustine/rituximab on the onset, magnitude, and duration of tumor control.
  
  
• Overall well-being [ Time Frame: Assessed until death regardless of cause. ] [ Designated as safety issue: Yes ]
  To assess the effect of the addition of idelalisib (GS-1101) to bendamustine/rituximab on measures of subject well-being, including overall survival, health related quality of life, and performance status
  
  
• Safety profile [ Time Frame: Assessed every 12 weeks until progression and 30 days post last dose. ] [ Designated as safety issue: Yes ]
  To describe the overall safety profile observed with the addition of idelalisib (GS-1101) to bendamustine/rituximab characterized by the type, frequency, severity, timing of onset, duration, and relationship to study therapy of any adverse events or abnormalities of laboratory tests; serious adverse events; or adverse events leading to discontinuation of study treatment
  
  

This is a Phase 3, multicenter, 2-arm, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the phosphatidylinositol 3-kinase delta (PI3K-delta) inhibitor idelalisib (GS-1101)GS-1101 in combination with bendamustine and Rituximab for previously treated indolent non-Hodgkin lymphomas.

Eligible subjects will be randomized with a 2:1 allocation to Regimen A vs. Regimen B.